Coeliac Disease and Immune Health - Wesley Research Institute
Wesley Research Institute

Wesley Research Institute is developing a world leading multi-disciplinary research program for Coeliac Disease and Immune Health.

About this research theme

An estimated 1 in 70 Australians have Coeliac Disease which is caused when an intolerance to gluten in wheat, rye and barley products triggers an autoimmune response that attacks the small intestine. However, it is estimated that more than 80 per cent of all Australian coeliac sufferers remain undiagnosed.

If left untreated, coeliac disease is associated with a three-fold increase in the risk of autoimmune diseases, osteoporosis, and malignancy, decreased quality of life, and a two to four-fold increase in mortality.

The disease can also lead to juvenile tooth decay, malnutrition, depression, and infertility. Patients with coeliac disease can experience a wide range of symptoms such as abdominal pain, bloating, diarrhoea, constipation, fatigue and weight loss.

Coeliac Research Network

Wesley Research Institute is developing a new research network focusing on Coeliac Disease and immune health research.
Through this network, we expect to bring together coeliac disease experts, like gastroenterologists, paediatric gastroenterologists, surgeons, dieticians, nutritionists, nurses and mucosal immunologists, to work together to really progress the multi-disciplinary research program.
More info
A coeliac diet

Coeliac Disease and Immune Health Research Objectives

Improve understanding

The Gluten Threshold Study is investigating whether there is an amount of gluten that coeliac patients can tolerate. The results will also help to influence food safety standards.

Creating communities

Through the new Coeliac Research Network, we hope to bring patients, clinicians and scientists together to really progress the multi-disciplinary research program.

to support research

Coeliac Disease and Immune Health Clinical Trials


The research project is to evaluate the safety, effectiveness, immune response and blood levels of a single subcutaneous (SC) dose of DONQ52, an investigational product, versus a placebo for use in the treatment of Coeliac Disease.

Dr Falk

A phase IIb, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet

Topas Therapeutics GmbH Study

A double-blind, randomized, placebo-controlled, phase 2a study  to evaluate the safety, tolerability, and pharmacodynamic (PD) effects of two infusions of escalating doses of TPM502 in adults diagnosed with Coeliac Disease (CeD).
Boy at dentist

Dental Enamel Defects Study

Evaluating the prevalence of Coeliac Disease in children with Developmental Defects of Enamel.
A person mixing baking ingredients in a bowl

Gluten Threshold Study

This study will compare small doses of gluten; Each participant is allocated either a dose of gluten or a placebo (which contains no gluten at all) through a process known as randomisation. The dose of gluten/placebo will be administered in a “gluten challenge”, which means that participants will ingest the gluten/placebo and then be observed for side effects.

TEVA Study

A single-dose phase 1b, randomized, double-blind, placebo-controlled study to characterise the safety and tolerability of TEV-53408 administered subcutaneously in adults with Coeliac Disease 

Our Research Goals

Research into faster and more accurate diagnosis

Improve understanding around the causes of disease and better prediction of disease progression

Increase survival and quality of life for patients and families

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram